SIREN : 429208440
MEDICA FONCIERE 28 is a French company founded 26 years ago, specialized in the sector Location de terrains et d'autres biens immobiliers. Based in VERTOU (44120), this company of category PME shows in 2024 a revenue of 860 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 859 963 € | 859 963 € | 859 963 € | 844 840 € | 844 840 € | 830 963 € | 821 029 € | 809 693 € | 807 432 € |
| Net income | 482 880 € | 458 283 € | 429 476 € | 399 301 € | 314 584 € | 283 868 € | 251 684 € | 194 968 € | 141 820 € |
| EBITDA | 799 524 € | 799 586 € | 801 226 € | 786 585 € | 792 014 € | 778 556 € | 767 961 € | 756 759 € | 756 768 € |
| Net margin | 56.2% | 53.3% | 49.9% | 47.3% | 37.2% | 34.2% | 30.7% | 24.1% | 17.6% |
In 2024, MEDICA FONCIERE 28 achieves revenue of 860 k€. Revenue is growing positively over 9 years (CAGR: +0.8%). Slight decline of 0% vs 2023. After deducting consumption (0 €), gross margin stands at 860 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 800 k€, representing 93.0% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 483 k€, i.e. 56.2% of revenue. This profit can be retained or distributed to shareholders.
859 963 €
859 963 €
799 524 €
646 017 €
482 880 €
93.0%
The debt ratio (= Financial debt / Equity x 100) stands at 11%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 89%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.2 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 74.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
10.523%
89.286%
74.001%
0.202
15.6%
In 2024, the debt ratio of MEDICA FONCIERE 28 (10.52) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of MEDICA FONCIERE 28 (89.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of MEDICA FONCIERE 28 (0.20) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
The liquidity ratio (= Current assets / Current liabilities) stands at 957.36. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.5x. Coverage is limited: any activity downturn would jeopardize interest payments.
957.357
1.52
In 2024, the liquidity ratio of MEDICA FONCIERE 28 (957.36) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of MEDICA FONCIERE 28 (1.5x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 125 days. Excellent situation: suppliers finance 125 days of the operating cycle (retail model). WCR is negative (-7 days): operations structurally generate cash. Notable WCR improvement over the period (-116%), freeing up cash.
-15 746 €
0 j
125 j
0 j
-7 j
Based on 169 transactions of similar company sales in 2024, the value of MEDICA FONCIERE 28 is estimated at 3 104 800 € (range 869 963€ - 5 577 690€). With an EBITDA of 799 524€, the sector multiple of 5.6x is applied. The price/revenue ratio is 0.81x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 169 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MEDICA FONCIERE 28 with other companies in the same sector:
Voir toutes les statistiques du secteur Location de terrains et d'autres biens immobiliers
The revenue of MEDICA FONCIERE 28 in 2024 is 860 k€.
Yes, MEDICA FONCIERE 28 generated a net profit of 483 k€ in 2024.
The headquarters of MEDICA FONCIERE 28 is located in VERTOU (44120), in the department Loire-Atlantique.
The tax return of MEDICA FONCIERE 28 is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MEDICA FONCIERE 28 operates in the sector Location de terrains et d'autres biens immobiliers (NAF code 68.20B). See the 'Sector positioning' section above to compare the company with its competitors.